Journal of Clinical Endocrinology & Metabolism最新文献

{"title":"Impact of Sleeve Gastrectomy on Skeletal Health: An Overlooked Concern.","authors":"Peter R Ebeling","doi":"10.1210/clinem/dgaf021","DOIUrl":"10.1210/clinem/dgaf021","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3901-e3902"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefits and Accuracy of Real-Time CGM in Children and Adolescents With Type 1 Diabetes Attending Summer Camp: Second Year.","authors":"Tatsuya Kondo, Takafumi Senokuchi, Mayumi Yano, Haruo Takeda, Kenro Nishida, Yutaka Kai, Naoto Kubota","doi":"10.1210/clinem/dgaf160","DOIUrl":"10.1210/clinem/dgaf160","url":null,"abstract":"<p><strong>Context: </strong>In 2023, we employed Dexcom G6 for real-time continuous glucose monitoring (rt-CGM); it showed high usefulness but unsatisfactory accuracy in summer camp (camp) participants with type 1 diabetes.</p><p><strong>Objective: </strong>To assess the usefulness, recommendation, and accuracy of a new rt-CGM system in camp participants in 2024.</p><p><strong>Methods: </strong>Sensor glucose (SG) concentrations were measured by Dexcom G7 (G7) from 6 days prior to camp. Usefulness and recommendation were assessed by questionnaire. A total of 21 children with type 1 diabetes and 52 healthcare providers (HCPs) participated. CGM-associated metrics were measured 6 days prior to camp (off camp: 6 days) and during camp (on camp: 2 days).</p><p><strong>Results: </strong>G7 was rated highly for its sensor insertion, visualization of SG variation, and convenience during camp. The SG value accuracy scored relatively low. G7's usefulness and recommendation among campers were significantly higher than those of G6, utilized the previous year, and they were both almost equally highly rated by HCPs. The mean absolute relative difference (MARD) was 11.3% (G6: 16.0%) on camp and 11.0% (G6: 19.7%) off camp. The coefficient of variation was 34.4% (G6: 60.3%) on camp and 35.9% (G6: 63.1%) off camp, while the glucose management indicator was 7.44% for G7 (G6: 8.04%). The glycemic management metrics on camp were better than those off camp. Graphical analyses also showed sufficient accuracy.</p><p><strong>Conclusion: </strong>G7 was rated higher in usefulness and recommendation than G6 among participants. G7 also exhibited improved accuracy and was considered a useful rt-CGM tool in a camp setting. Glucose management on camp was significantly improved because of the multi-directional efforts of the HCPs.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"3074-3083"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules.","authors":"Apoorva Aekka, Nicoleta C Arva, He Zhen Ren, Mehul Raval, Jeffrey Rastatter, Sydney Finkelstein, Venkata Arun Timmaraju, Jami L Josefson","doi":"10.1210/clinem/dgaf110","DOIUrl":"10.1210/clinem/dgaf110","url":null,"abstract":"<p><strong>Context: </strong>Molecular analysis of thyroid cytopathology derived from fine needle aspiration (FNA) improves diagnostic yield and informs presurgical treatment stratification of adults with thyroid nodules. Its use is limited in pediatrics, but it has the potential to guide clinical management for these patients.</p><p><strong>Objective: </strong>To report on the results of oncogene sequencing and microRNA (miRNA)-based risk classification of thyroid FNA cytopathology in a pediatric cohort.</p><p><strong>Design: </strong>Retrospective analysis of archived FNA samples collected from patients seen at Lurie Children's Hospital between October 2020 and March 2023; 39 cases were included in the study.</p><p><strong>Setting: </strong>Referral center.</p><p><strong>Patients: </strong>Thirty-seven patients ages 7 to 20 years (mean age 13.9 years).</p><p><strong>Interventions: </strong>Interpace Diagnostics®' multiplatform testing including ThyGeNEXT® (oncogene panel) and ThyraMIR® (miRNA risk classifier) was performed on FNA samples. Molecular results were compared to final surgical pathology or repeat FNA results.</p><p><strong>Main outcome measures: </strong>Description of cohort molecular characteristics; test sensitivity and specificity.</p><p><strong>Results: </strong>The most common oncogenic alterations among malignant cases were the BRAFV600E variant (38%), RET-PTC1 fusions (14%), and NRAS variants (14%). Nineteen of 21 malignant samples had positive (high-risk) miRNA expression profiles. Fifteen of 18 benign cases had negative (low-risk) miRNA profiles. Multiplatform molecular testing demonstrated 90.5% sensitivity and 88.9% specificity in detecting malignant pathology.</p><p><strong>Conclusion: </strong>This is the first study to report on the use of combined oncogene and miRNA analysis of FNA cytopathology in a pediatric cohort. Multiplatform molecular testing is a potentially useful adjunct to FNA as a presurgical diagnostic tool in the evaluation of pediatric thyroid nodules.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3738-e3744"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing OGTT: Unlocking the Real-Time Insights and Expanded Data of Continuous Glucose Monitoring.","authors":"Sujatha Seetharaman, Laya Ekhlaspour","doi":"10.1210/clinem/dgaf068","DOIUrl":"10.1210/clinem/dgaf068","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3897-e3898"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency Ablation for Thyroid Nodules (RATED Study)-Analysis of a Learning Curve and Predictors of Success.","authors":"Manon M D van der Meeren, Tim Boers, Pim de Graaf, Katya M Duvivier, Koen M A Dreijerink, Laura N Deden, Peter Veendrick, Paul Cernohorsky, Frank B M Joosten, Angelique B M C Savelberg, Sicco J Braak, Sean H P P Roerink, Michel Versluis, Srirang Manohar, Wim J G Oyen","doi":"10.1210/clinem/dgaf058","DOIUrl":"10.1210/clinem/dgaf058","url":null,"abstract":"<p><strong>Context: </strong>Radiofrequency ablation (RFA) is used as treatment for symptomatic thyroid nodules. Factors influencing the volume reduction ratio (VRR) at 12 months are not yet fully understood.</p><p><strong>Objective: </strong>The primary objective of this work was evaluating the VRR at 12 months after RFA. Secondary objectives were the assessment of a learning curve and factors influencing the VRR at 12 months.</p><p><strong>Methods: </strong>A retrospective observational cohort study was conducted at 3 Dutch referral hospitals of patients who underwent RFA for symptomatic thyroid nodules with available ultrasound (US) follow-up. Main outcome measures included US-based VRR at 12 months and chronologically numbered RFA procedures. All patients' baseline, treatment, and early follow-up factors were assessed for correlation with VRR at 12 months.</p><p><strong>Results: </strong>A total of 337 patients with 356 nodules were included in the learning curve analysis. VRR at 12 months increased for the first 20 treatments per center and stabilized thereafter, indicating a plateau phase after a learning curve. These initial cases were removed from further analysis. In the remaining 299 nodules, median VRR at 3, 6, and 12 months was 57.1%, 65.6%, and 70.8%. Baseline nodule volume negatively correlated with VRR at 12 months but VRR was high for every volume category. Energy delivered per volume did not correlate with VRR.</p><p><strong>Conclusion: </strong>In RFA for thyroid nodules, a stable treatment efficacy is achieved after 20 treatments, with a median VRR of 70.8%. Baseline nodule volume, energy delivered, and prolonged follow-up 6 months after treatment may not be clinically relevant to predict treatment success.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"3201-3209"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Esterified Fatty Acid Profiles and Cause-Specific Mortality: The Cardiovascular Health Study.","authors":"Yakubu Bene-Alhasan, Sanyog G Shitole, Petra Bůžková, Calvin H Hirsch, Joachim H Ix, Jorge R Kizer, David S Siscovick, Nirupa R Matthan, Alice H Lichtenstein, Luc Djoussé, Kenneth J Mukamal","doi":"10.1210/clinem/dgaf182","DOIUrl":"10.1210/clinem/dgaf182","url":null,"abstract":"<p><strong>Context: </strong>Total fasting non-esterified fatty acid (NEFA) levels have been associated with mortality. The corresponding associations with NEFA levels following an oral glucose tolerance test (OGTT) and with individual fasting NEFA species are unclear.</p><p><strong>Objective: </strong>We evaluated the associations of post-load NEFA, fasting subclasses and individual NEFA with mortality.</p><p><strong>Methods: </strong>The Cardiovascular Health Study is a population-based cohort study of community-dwelling adults over 64 years of age from 4 US communities that began in 1989-1990. Participants had total NEFA measured enzymatically before and 2 hours after an OGTT from archived serum samples collected in 1996-1997. Fasting individual NEFA were also measured using gas chromatography. Cox proportional hazard models were used to evaluate adjusted hazard ratios (aHR) for mortality associated with fasting and post-load total NEFA, and fasting individual and fatty acid subclasses (saturated, monounsaturated, n-3 and n-6 polyunsaturated, and trans).</p><p><strong>Results: </strong>The final population included 1996 participants (mean age 78 years; 60.5% female). Over a median 11-year follow-up period, 1678 participants died. Total fasting NEFA was associated with higher risk of all-cause mortality (aHR per SD: 1.17, 95% CI [1.10-1.23]). Total post-load NEFA was not associated with mortality. Among subclasses, only monounsaturated fatty acid (MUFA) was associated with total mortality (aHR 1.24, 95% CI [1.09-1.41]). For individual NEFAs, nervonic acid (aHR 1.06, 95% CI [1.01-1.12]), petroselaidic acid (aHR 1.21, 95% CI [1.03-1.42]), and eicosapentaenoic acid (aHR 0.90, 95% CI [0.82-0.99]) were associated with all-cause mortality.</p><p><strong>Conclusion: </strong>Individual fasting NEFAs represent attractive candidates for medical and public health interventions aimed at improving survivorship in older adults and should be investigated further.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3577-e3586"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fiber Intervention Study in Prader-Willi Syndrome: Insights into Metabolic and Microbiota Shifts.","authors":"Qiming Tan, Ye Peng, Edward C Deehan, Flavio T Vieira, Brian Wan Ping Ho, Shima Afhami, Eytan Wine, Karen L Madsen, Catherine J Field, Mohammadreza Pakseresht, Olga Ilkayeva, Christopher B Newgard, Jens Walter, Hein Min Tun, Andrea M Haqq","doi":"10.1210/clinem/dgaf142","DOIUrl":"10.1210/clinem/dgaf142","url":null,"abstract":"<p><strong>Context: </strong>While increased fiber intake may benefit appetite and metabolism in the general population, its effects in individuals with Prader-Willi syndrome (PWS), a condition characterized by hyperphagia, obesity, and metabolic dysregulation, remain to be explored.</p><p><strong>Objective: </strong>This study assessed the effects of a fiber intervention on hyperphagia, metabolic health, and gut microbiota in individuals with PWS, and explored associations between changes in health markers and shifts in microbiota.</p><p><strong>Methods: </strong>Participants received either a high-dose fiber intervention (35 g/day) or a control for 3 weeks. Following a washout period of 4 to 8 weeks, participants switched treatments for another 3 weeks. Fecal (bacterial 16S ribosomal RNA) and blood (immunometabolic markers, targeted metabolomics) samples were collected before and after each treatment.</p><p><strong>Results: </strong>Fourteen participants (with a median age of 13.6 years, 8 [57.1%] were female) reported high tolerance to the fiber intervention. While it did not significantly alter hyperphagia or key metabolic markers, the fiber intervention led to shifts in gut microbiota diversity and increased the abundance of beneficial bacteria, such as Bifidobacterium longum and Faecalibacterium prausnitzii. Additionally, it altered fecal and serum metabolites, including a decrease in branched-chain fatty acids and an increase in serum C4-OH acylcarnitine.</p><p><strong>Conclusion: </strong>While this study did not observe significant changes in primary or secondary endpoints, it suggests that a short-term high-fiber intervention may induce beneficial shifts in gut microbiota and microbial metabolites in individuals with PWS. Further research is warranted to investigate the long-term effects and potential therapeutic applications of fiber interventions in PWS.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"3120-3132"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome.","authors":"Henrik Elenius, Raven McGlotten, Chuong D Hoang, Clara C Chen, Corina Millo, Ahmed M Gharib, Lynnette K Nieman","doi":"10.1210/clinem/dgaf114","DOIUrl":"10.1210/clinem/dgaf114","url":null,"abstract":"<p><strong>Context: </strong>Identification of tumors causing ectopic ACTH syndrome (EAS) is challenging. 68Ga-DOTATATE (DOTA) and 18F-DOPA (DOPA) positron emission tomography/computed tomography (PET/CT) scans are promising imaging modalities warranting further evaluation.</p><p><strong>Objective: </strong>This work aimed to compare DOTA and DOPA PET/CT performance in detecting ectopic sources of adrenocorticotropin (ACTH).</p><p><strong>Methods: </strong>A prospective comparison of DOTA, DOPA, and conventional imaging modalities in EAS was conducted at a tertiary referral center. Participants included 24 patients with EAS from neuroendocrine tumors confirmed by pathology and/or biochemical cure. Interventions included DOTA PET/CT, DOPA PET/CT, CT, MRI, gated cardiac CT/MRI, and Octreoscan (OCT) performed between 2014 and 2024. Main outcome measures included sensitivity (Se) and positive predictive value (PPV) for each imaging modality, and 7 combinations thereof, in patients with identified tumors.</p><p><strong>Results: </strong>Of functional scans, Se for DOPA was higher than OCT (Se 88%; 95% CI, 67%-97% vs 31%; 95% CI, 10%-61%) and overlapped DOTA (Se 79%; 95% CI, 57%-92%). Among structural modalities, CT had the highest Se (96%; 95% CI, 76%-100%) when interpreted knowing results of functional scans; Se was 57% (95% CI, 35%-76%) without those data. Cardiac CT/MRI had the highest PPV (100% for each). Combinations of CT/MRI plus DOTA and/or DOPA provided high PPVs (89%-100%) with Se 64% to 87%; all CIs overlapped. Combined CT and MRI without functional scans provided PPV 79% with Se 55%, although CI overlapped with combinations that included DOTA/DOPA.</p><p><strong>Conclusion: </strong>DOTA and DOPA improve tumor detection in EAS by increasing Se of structural scans and PPV of detected lesions. The two scans are complementary and should be integral to imaging strategies for EAS. However, DOPA is not currently approved by the Food and Drug Administration for this indication.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3794-e3802"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors.","authors":"Andrew L Lin, Vasilisa Rudneva, Adam Newton, Nazanin K Majd, Rajiv Magge, Soma Sengupta, Bernard Goichot, Anna Piotrowski, Igor Gavrilovic, Odelia Cooper, Marc Rosenblum, Thomas Kaley, Ingo Mellinghoff, Robert J Young, Mark T A Donoghue, Viviane Tabar, Eliza B Geer","doi":"10.1210/clinem/dgaf178","DOIUrl":"10.1210/clinem/dgaf178","url":null,"abstract":"<p><strong>Context: </strong>Pituitary neuroendocrine tumors (PitNETs) that progress following surgery and radiotherapy are in need of additional treatment options. Responses to immune checkpoint inhibitors (ICIs) have been described; however, the feasibility of ICI therapy and biomarkers of response have not been formally assessed.</p><p><strong>Objective: </strong>To evaluate the activity of ICI as a treatment for PitNETs.</p><p><strong>Methods: </strong>We performed a single-center, prospective, phase 2 trial investigating the activity of ipilimumab and nivolumab in patients with PitNETs. The primary endpoint was objective response using the iRANO response criteria. We then explored genetic biomarkers of response to ICIs in 13 patients with PitNETs who were treated with ICIs, on or outside of the trial.</p><p><strong>Results: </strong>Ten patients with a PitNET were enrolled, including 5 corticotroph, 4 lactotroph, and 1 somatotroph tumor, of which 9/10 (4 metastatic and 5 nonmetastatic) patients were evaluable for the primary endpoint. While no objective responses were observed, tumor shrinkage was seen in 2/9 patients. In a biomarker discovery cohort, comprising 7 tumors treated on trial and 6 tumors treated off trial, temozolomide hypermutation, and mismatch repair deficiency (MMRd) were associated with immunological response. In 3 tumors sequenced pre- and post-ICI treatment, we identified evidence of immunoediting, characterized by loss of MMRd and/or a decrease in tumor mutational burden.</p><p><strong>Conclusion: </strong>This study demonstrates the safety and feasibility of ICI treatment in aggressive PitNETs. We also identified MMRd and temozolomide hypermutation as potential biomarkers of response to ICI. Overall, our data suggest that ICIs might provide an additional treatment option for PitNET; this should be evaluated more broadly in future studies.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"3066-3073"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12527438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Heterogeneity and Transitions of Obesity in Mexico.","authors":"Adrian Soto-Mota, Rodrigo M Carrillo-Larco, Edward Gregg, Rosalba Rojas-Martínez, Majid Ezzati, Carlos Aguilar-Salinas","doi":"10.1210/clinem/dgaf158","DOIUrl":"10.1210/clinem/dgaf158","url":null,"abstract":"<p><strong>Context: </strong>There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated comorbidities are lacking.</p><p><strong>Objective: </strong>We estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years.</p><p><strong>Methods: </strong>We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS), which assesses 3 dimensions (medical, mental, and functional) across 5 incremental severity stages, by sex and age groups, were estimated across all included surveys. Metabolically healthy obesity (MHO) was defined as the absence of diabetes, dyslipidemia, and hypertension.</p><p><strong>Results: </strong>A total of 20 758 participants were analyzed. Mean body mass index (BMI) increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among MHO individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, MHO was less likely as age and BMI increased.</p><p><strong>Conclusion: </strong>The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the aging of the population will cause additional burdens to the population and the health system.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3648-e3655"},"PeriodicalIF":5.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}